Trial Profile

A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apremilast (Primary)
Indications Plaque psoriasis
Focus Adverse reactions; Pharmacokinetics
Sponsors Amgen; Celgene Corporation

Most Recent Events

20 Aug 2019 Status changed from active, no longer recruiting to completed.
10 Aug 2019 Results published in the Journal of the American Academy of Dermatology
25 Jun 2018 Planned End Date changed from 15 Nov 2019 to 5 Aug 2019.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com